BridgeBio Pharma Inc.
BridgeBio Pharma Announces $250 Million Public Offering
Summary
On March 5, 2024, BridgeBio Pharma, Inc. announced an underwritten public offering of $250 million of its common stock, with an additional option for underwriters to purchase up to $37.5 million more. The proceeds will be used for the commercial launch of acoramidis, clinical and pre-clinical development, research activities, and general corporate purposes. This offering is part of the company's effective shelf registration statement on Form S-3ASR and is expected to close on or about March 8, 2024. Press releases for the launch and pricing of the offering are attached as Exhibits 99.1 and 99.2.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (4)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement